Indegene Ltd
Indegene Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #20 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Indegene is comfortable and confident about its current engagement pipeline and growth trajectory.
From Indegene Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Indegene is comfortable and confident about its current engagement pipeline and growth trajectory.
- Industry consolidation and COVID-related slowdowns are easing; customers are returning to invest in programs.
- Priority focus is on growth through reinvestment and strategic investments.
- The company expects growth from existing top customers (top 5 and top 20), which remain stable or growing.
- New deal wins and expanding client conversations indicate a positive future revenue pipeline.
- Tectonic, a transformative deal construct, has started generating revenue, expected to scale in coming quarters.
- Client pyramid expected to strengthen over the next few quarters, with increasing million-dollar customers and active client counts.
- Organic revenue growth is substantial with tuck-in acquisitions complementing growth.
2 more points from Indegene Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Indegene Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indegene's priority for reinvestment and investment is growth, particularly post-COVID industry consolidation and easing customer pressures (Page 17).
- Focus on doubling down on investment in areas like Tectonic (their AI-driven platform), Gen AI, and expanding organic capabilities (Page 13, 16).
- Medium- to long-term growth initiatives include building AI-based products and tools incorporated into their solutions (Page 5).
2 more points from Indegene Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indegene Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Manish Gupta expressed comfort and confidence in the current engagement pipeline of Indegene and the company's growth trajectory.
- He emphasized that after subdued activity during and post-COVID until 2023, industry consolidation and customer slowdown are easing.
- Customers are returning with clearer direction, making investment in growth a top priority for Indegene.
- Suhas Prabhu reaffirmed the stable and growing status of top 5 and top 20 customers.
- Deal wins from prior quarters are converting to revenue, indicating a positive outlook for the overall pipeline.
2 more points from Indegene Ltd's call on order book
Create a free account to keep reading this call
Indegene Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.1K Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indegene Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwals Health Care Ltd (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene Intl. (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Indegene Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indegene Ltd Q1 FY26 results?
Indegene is comfortable and confident about its current engagement pipeline and growth trajectory.
What is Indegene Ltd share price analysis?
Indegene Ltd currently shows a neutral. The stock trades at a P/E of 31.3 with a market cap of ₹13,016 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene Ltd planning capital expenditure?
Indegene's priority for reinvestment and investment is growth, particularly post-COVID industry consolidation and easing customer pressures (Page 17).
Keep Indegene Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.